Vertex’s $10 B Deal for Crinetics Brings Game‑Changing Acromegaly and Rare Disease Drugs to Its Pipeline
Vertex’s $10 billion acquisition of Crinetics adds the FDA‑approved acromegaly drug PALSONIFY and rare‑disease pipeline assets, boosting its endocrinology portfolio and growth outlook.
- CRINETICS PHARMACEUTICALS IN
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read